Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Nowakowski on Evolving Treatment Paradigm of MCL

Grzegorz S. Nowakowski, MD
Published: Thursday, Apr 20, 2017



Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

MCL is an area where a lot of new agents are being developed, Nowakowski explains. Moreover, what is interesting is that there is a paradigm shift from chemotherapy-based combinations to targeted therapy-based regimens in the relapsed setting. These include ibrutinib (Imbruvica) plus rituximab (Rituxan) and lenalidomide (Revlimid) and rituximab. Venetoclax (Venclexta) is another agent being explored in these regimens.

Over time, some of these more novel regimens are likely to replace chemotherapy in the relapsed setting, he adds..


Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

MCL is an area where a lot of new agents are being developed, Nowakowski explains. Moreover, what is interesting is that there is a paradigm shift from chemotherapy-based combinations to targeted therapy-based regimens in the relapsed setting. These include ibrutinib (Imbruvica) plus rituximab (Rituxan) and lenalidomide (Revlimid) and rituximab. Venetoclax (Venclexta) is another agent being explored in these regimens.

Over time, some of these more novel regimens are likely to replace chemotherapy in the relapsed setting, he adds..



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x